Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's DiseaseSamantha Budd Haeberlein, Alfred Sandrock, Paul Aisen et al.|The Journal of Prevention of Alzheimer s Disease|2022Cited by 1.3k
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trialJacob Elkins, Mitchell S.V. Elkind, Maarten G. Lansberg et al.|The Lancet Neurology|2017Cited by 213
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsTatiana Plavina, Bruce Cree, Kumar Kandadi Muralidharan et al.|Neurology|2017Cited by 92